1. Design and Synthesis of Inhibitors of Plasmodium falciparum N-Myristoyltransferase, A Promising Target for Antimalarial Drug Discovery
- Author
-
D.K. Moss, Z. Yu, Andrzej M. Brzozowski, Anthony J. Wilkinson, Anthony A. Holder, Edward W. Tate, James A. Brannigan, and Robin J. Leatherbarrow
- Subjects
Models, Molecular ,MECHANISM ,Protein Conformation ,Plasmodium falciparum ,SELECTIVE INHIBITORS ,Chemistry, Medicinal ,Pharmacology ,medicine.disease_cause ,Crystallography, X-Ray ,Article ,STARTING POINTS ,Antimalarials ,Structure-Activity Relationship ,ADP-RIBOSYLATION FACTOR ,MALARIA ,Piperidines ,parasitic diseases ,Drug Discovery ,medicine ,Structure–activity relationship ,Potency ,Transferase ,Humans ,Pharmacology & Pharmacy ,Candida albicans ,chemistry.chemical_classification ,CANDIDA-ALBICANS ,Mutation ,Science & Technology ,MYRISTOYL-COA ,biology ,IDENTIFICATION ,Drug discovery ,Stereoisomerism ,biology.organism_classification ,ESSENTIAL ENZYME ,Enzyme ,chemistry ,Biochemistry ,Drug Design ,BENZOFURANS ,Mutagenesis, Site-Directed ,Molecular Medicine ,Life Sciences & Biomedicine ,Acyltransferases - Abstract
Design of inhibitors for N-myristoyltransferase (NMT), an enzyme responsible for protein trafficking in Plasmodium falciparum , the most lethal species of parasites that cause malaria, is described. Chemistry-driven optimization of compound 1 from a focused NMT inhibitor library led to the identification of two early lead compounds 4 and 25, which showed good enzyme and cellular potency and excellent selectivity over human NMT. These molecules provide a valuable starting point for further development.
- Published
- 2012